Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of diphtheria-tetanus vaccine on immune response to hepatitis B vaccine in non-responder dialysis patients
IRCT138812093454N1Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of diphtheria toxoid adsorbed + tetanus toxoid adsorbed in hepatitis B (HBV) and end-stage kidney disease (ESKD), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Serologic response to hepatitis B vaccine. Started Mar 2009; status: completed.
02
Drugs
diphtheria toxoid adsorbed + tetanus toxoid adsorbed
03
Conditions
hepatitis B (HBV)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT138812093454N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT138812093454N1.